vemurafenib

GPTKB entity

Statements (61)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:administered_by oral tablet
gptkbp:approves gptkb:2011
gptkb:FDA
gptkbp:brand gptkb:Zelboraf
gptkbp:chemical_formula C23 H27 Cl F2 N2 O2 S
gptkbp:class gptkb:Atom
gptkbp:clinical_trial gptkb:BRIM-2
gptkb:BRIM-3
gptkb:BRIM-4
Phase III
BRIM-1
gptkbp:clinical_use advanced melanoma
gptkbp:contraindication severe liver impairment
hypersensitivity to vemurafenib
gptkbp:discovered_by gptkb:Genentech
gptkbp:dosage_form gptkb:tablet
gptkbp:drug_interactions CYP3 A4 inducers
CYP2 C9 inhibitors
https://www.w3.org/2000/01/rdf-schema#label vemurafenib
gptkbp:indication gptkb:BRAF_V600_E_mutation-positive_melanoma
gptkbp:invention patented
gptkbp:lifespan 57 hours
gptkbp:marketed_as gptkb:Roche
gptkbp:mechanism_of_action BRAF inhibitor
gptkbp:metabolism liver
gptkbp:pharmacokinetics highly protein-bound
inhibits cell proliferation
induces apoptosis
gptkbp:production_status marketed
gptkbp:research_areas oncology
pharmacogenomics
gptkbp:route_of_administration oral
gptkbp:safety_measures hepatotoxicity
QT prolongation
ocular toxicity
risk of new malignancies
gptkbp:side_effect gptkb:anemia
fatigue
headache
nausea
vomiting
diarrhea
joint pain
constipation
skin rash
hypoglycemia
photosensitivity
cardiac arrhythmias
alopecia
hyperglycemia
thromboembolism
hypersensitivity reactions
elevated liver enzymes
musculoskeletal pain
pruritus
gptkbp:targets gptkb:BRAF_V600_E_mutation
gptkbp:used_for treatment of melanoma
gptkbp:bfsParent gptkb:Cotellic
gptkb:Zelboraf
gptkbp:bfsLayer 6